Physician profile
Dan J Fintel
NPI 1992740328
$118,807.46
in general payments reported to CMS, 2019-2025
27 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $17K · 2021: $19K · 2022: $16K · 2023: $11K · 2024: $1,765 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,865 · Food and Beverage: $4,675 · Consulting Fee: $199 · Travel and Lodging: $42.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,865.00 |
| Food and Beverage | $4,675.38 |
| Consulting Fee | $199.00 |
| Travel and Lodging | $42.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $89,124.62 | 2019-2023 | Xarelto |
| Pfizer INC. | $11,719.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $7,359.84 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $3,487.53 | 2019-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $1,420.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,036.38 | 2019 | |
| Amgen INC. | $834.02 | 2019-2024 | Repatha, Corlanor |
| Altathera Pharmaceuticals LLC | $600.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.47 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $521.92 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $401.40 | 2019-2024 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $266.70 | 2024-2025 | |
| Chiesi USA, INC. | $253.00 | 2019-2023 | Cleviprex, Kengreal |
| Janssen Scientific Affairs, LLC | $248.23 | 2019-2022 | |
| Ge Healthcare | $199.00 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $152.26 | 2019 | |
| Merck Sharp & Dohme LLC | $152.16 | 2019-2023 | Verquvo |
| Esperion Therapeutics, INC. | $83.05 | 2020-2024 | Nexletol |
| Akcea Therapeutics, INC. | $66.50 | 2019 | |
| Novo Nordisk INC | $66.14 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $60.93 | 2023-2024 | Inpefa |
| Abiomed | $52.42 | 2019-2021 | |
| Janssen Biotech, INC. | $42.64 | 2024 | Stelara |
| Madrigal Pharmaceuticals | $42.19 | 2025 | Rezdiffra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.72 | 2024 | Lifevest |
| Mannkind Corporation | $18.08 | 2023 | Afrezza |
| Kiniksa Pharmaceuticals, Ltd. | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Fintel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.